Krett N L, Pillay S, Moalli P A, Greipp P R, Rosen S T
Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois 60611, USA.
Cancer Res. 1995 Jul 1;55(13):2727-9.
In multiple myeloma cells resistant to glucocorticoids, we have previously identified a variant glucocorticoid receptor (GR) transcript (P. A. Moalli et al., Cancer Res., 53: 3877-3879, 1993). Here, we report a reverse transcription-PCR assay to assess whether this aberrant GR transcript is present in myeloma patients. We detected both the wild-type and variant GR transcripts in the patient isolate that was the source of our myeloma cell lines, in patients refractory to steroid treatment, and in healthy control subjects. Simultaneous amplification of wild-type and variant GR mRNAs indicates that the variant GR is more highly expressed in cells that are resistant to glucocorticoids. We hypothesize that the variant GR is a normal mRNA transcript that acts to modulate glucocorticoid responsiveness, and increased expression contributes to a resistant phenotype.
在对糖皮质激素耐药的多发性骨髓瘤细胞中,我们之前已鉴定出一种变异的糖皮质激素受体(GR)转录本(P.A. 莫阿利等人,《癌症研究》,53: 3877 - 3879, 1993)。在此,我们报告一种逆转录 - 聚合酶链反应检测方法,以评估这种异常的GR转录本是否存在于骨髓瘤患者中。我们在作为我们骨髓瘤细胞系来源的患者分离物、对类固醇治疗难治的患者以及健康对照受试者中检测到了野生型和变异型GR转录本。野生型和变异型GR mRNA的同时扩增表明,变异型GR在对糖皮质激素耐药的细胞中表达更高。我们推测变异型GR是一种正常的mRNA转录本,其作用是调节糖皮质激素反应性,且表达增加促成了耐药表型。